Inpatient versus outpatient hypomethylating agent induction for acute myeloid leukemia as a predictor for survival

•Inpatient hypomethylating agent (HMA) therapy for AML may carry an inherently higher risk of mortality.•The cause for admission, mostly neutropenic fever and hyperleukocytosis, may be a reason for this increased risk.•We advise physicians who are administering IP HMA to consider its’ inherent risk associated with its’ administration.